US2021187216A1PendingUtilityA1

Nasal Administration

73
Assignee: OPTINOSE ASPriority: Apr 5, 2007Filed: Jul 27, 2020Published: Jun 24, 2021
Est. expiryApr 5, 2027(~0.7 yrs left)· nominal 20-yr term from priority
Inventors:Per Gisle DjupeslandRoderick Peter Hafner
A61K 31/4045A61M 2210/0625A61M 2210/0618A61M 2205/3606A61M 2202/064A61M 15/08A61M 16/0808A61M 16/1055A61M 15/0005A61M 16/1045A61M 15/0028A61M 15/0098A61M 15/0021A61M 15/0041A61M 15/003A61M 16/1065A61M 15/0035A61M 15/0008
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece.

Claims

exact text as granted — not AI-modified
1 . A delivery device for delivering a powdered substance to the posterior region of a nasal cavity of a subject, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which a powdered substance is delivered to the posterior region of the nasal cavity of the subject; and a substance supply unit which is operable to deliver a powdered substance through the nosepiece. 
     
     
         2 - 92 . (canceled)

Join the waitlist — get patent alerts

Track US2021187216A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.